EUVIMEDEUVIMED entdecken
Open Access

Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage

Mark Jackson, Niousha Ahmari, Jianqiang Wu iD, Tilat A Rizvi, Elizabeth Fugate, Mi-Ok Kim, Eva Dombi, Heribert Arnhof, Guido Boehmelt, Matthias J Düchs, Clive J Long, Udo Maier und 3 weitere

The Journal of Pharmacology and Experimental Therapeutics · 2023-05 · 385 (2) · 106-116

DOI: 10.1124/jpet.122.001431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023-05. Verfasst von Mark Jackson und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute (M.J., N.A., J.W., T.A.R., N.R.) and Department of Radiol…. Hauptthemen laut MEDLINE: Neurofibroma, Neurofibroma, Plexiform, Neurofibromatosis 1. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Individuals with neurofibromatosis type 1 develop rat sarcoma virus (RAS)-mitogen-activated protein kinase-mitogen-activated and extracellular signal-regulated kinase (RAS-MAPK-MEK)-driven nerve tumors called neurofibromas. Although MEK inhibitors transiently reduce volumes of most plexiform neurofibromas in mouse models and in neurofibromatosis type 1 (NF1) patients, therapies that increase the efficacy of MEK inhibitors are needed. BI-3406 is a small molecule that prevents Son of Sevenless (SOS)1 interaction with Kirsten rat sarcoma viral oncoprotein (KRAS)-GDP, interfering with the RAS-MAPK cascade upstream of MEK. Single agent SOS1 inhibition had no significant effect in the DhhCre;Nf1 fl/fl mouse model of plexiform neurofibroma, but pharmacokinetics (PK)-driven combination of selumetinib with BI-3406 significantly improved tumor parameters. Tumor volumes and neurofibroma cell proliferation, reduced by MEK inhibition, were further reduced by the combination. Neurofibromas are rich in ionized calcium binding adaptor molecule 1 (Iba1)+ macrophages; combination treatment resulted in small and round macrophages, with altered cytokine expression indicative of altered activation. The significant effects of MEK inhibitor plus SOS1 inhibition in this preclinical study suggest potential clinical benefit of dual targeting of the RAS-MAPK pathway in neurofibromas. SIGNIFICANCE STATEMENT: Interfering with the RAS-mitogen-activated protein kinase (RAS-MAPK) cascade upstream of mitogen activated protein kinase kinase (MEK), together with MEK inhibition, augment effects of MEK inhibition on neurofibroma volume and tumor macrophages in a preclinical model system. This study emphasizes the critical role of the RAS-MAPK pathway in controlling tumor cell proliferation and the tumor microenvironment in benign neurofibromas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurofibromaNeurofibroma, PlexiformNeurofibromatosis 1AnimalsMiceDisease Models, AnimalExtracellular Signal-Regulated MAP KinasesMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)Tumor MicroenvironmentSOS1 Protein

Substanzen

Extracellular Signal-Regulated MAP KinasesMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)SOS1 Protein

Autor:innen und Institutionen

  • Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute (M.J., N.A., J.W., T.A.R., N.R.) and Department of Radiology (E.F.), Cincinnati Children's Hospital Medical Center, Cincinnati,…

ORCID-Profile: Jianqiang Wu

Förderung

  • NINDS NIH HHS

Zitieren

APA

Jackson, M., Ahmari, N., Wu, J., Rizvi, T. A., Fugate, E., Kim, M. O., Dombi, E., Arnhof, H., Boehmelt, G., Düchs, M. J., Long, C. J., Maier, U., Trapani, F., Hofmann, M. H., & Ratner, N. (2023). Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. The Journal of Pharmacology and Experimental Therapeutics, 385(2), 106-116. https://doi.org/10.1124/jpet.122.001431

Vancouver

Jackson M, Ahmari N, Wu J, Rizvi TA, Fugate E, Kim MO, et al. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. The Journal of Pharmacology and Experimental Therapeutics. 2023;385(2):106-116. doi:10.1124/jpet.122.001431

BibTeX
@article{Jackson2023,
  author = {Jackson, Mark and Ahmari, Niousha and Wu, Jianqiang and Rizvi, Tilat A and Fugate, Elizabeth and Kim, Mi-Ok and Dombi, Eva and Arnhof, Heribert and Boehmelt, Guido and Düchs, Matthias J and Long, Clive J and Maier, Udo and Trapani, Francesca and Hofmann, Marco H and Ratner, Nancy},
  title = {Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2023},
  volume = {385},
  number = {2},
  pages = {106--116},
  doi = {10.1124/jpet.122.001431}
}
Kostenlos starten →